136 related articles for article (PubMed ID: 6621715)
1. Drugs for Parkinson's disease reduce tremor induced by physostigmine.
Gothóni P; Lehtinen M; Fincke M
Naunyn Schmiedebergs Arch Pharmacol; 1983 Jul; 323(3):205-10. PubMed ID: 6621715
[TBL] [Abstract][Full Text] [Related]
2. Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges.
Schrag A; Schelosky L; Scholz U; Poewe W
Mov Disord; 1999 Mar; 14(2):252-5. PubMed ID: 10091618
[TBL] [Abstract][Full Text] [Related]
3. Anti-nicotinic properties of anticholinergic antiparkinson drugs.
Gao ZG; Liu BY; Cui WY; Li LJ; Fan QH; Liu CG
J Pharm Pharmacol; 1998 Nov; 50(11):1299-305. PubMed ID: 9877318
[TBL] [Abstract][Full Text] [Related]
4. Quantification of tremor in rats induced by physostigmine.
Gothóni P; Lehtinen M; Silen L
Psychopharmacology (Berl); 1981; 74(3):275-9. PubMed ID: 6791238
[TBL] [Abstract][Full Text] [Related]
5. Effects of selective central muscarinic blockade on schedule-controlled behavior and on the rate-decreasing effects of physostigmine.
Hymowitz N; Brezenoff HE
Pharmacol Biochem Behav; 1984 Jul; 21(1):109-15. PubMed ID: 6463084
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characteristics of catalepsy induced by intracerebroventricular administration of histamine in mice: the importance of muscarinic step in central cholinergic neurons.
Onodera K; Shinoda H
Agents Actions; 1991 May; 33(1-2):143-6. PubMed ID: 1897431
[TBL] [Abstract][Full Text] [Related]
7. The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954.
Coward DM; Doggett NS
Psychopharmacology (Berl); 1977 Apr; 52(2):165-71. PubMed ID: 407600
[TBL] [Abstract][Full Text] [Related]
8. Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.
Zarrindast MR; Poursoltan M
Br J Pharmacol; 1989 Apr; 96(4):843-8. PubMed ID: 2663110
[TBL] [Abstract][Full Text] [Related]
9. Ethanol withdrawal tremor does not interact with physostigmine-induced tremor in rat.
Gothoni P
Pharmacol Biochem Behav; 1985 Sep; 23(3):339-44. PubMed ID: 4048228
[TBL] [Abstract][Full Text] [Related]
10. Functional reactivity of central cholinergic systems following desipramine treatments and sleep deprivation.
Murugaiah KD; Ukponmwan OE
Naunyn Schmiedebergs Arch Pharmacol; 2003 Oct; 368(4):294-300. PubMed ID: 13680087
[TBL] [Abstract][Full Text] [Related]
11. Modification of the tremorigenic activity of physostigmine.
Ambrani LM; Van Woert MH
Br J Pharmacol; 1972 Oct; 46(2):344-7. PubMed ID: 4651776
[TBL] [Abstract][Full Text] [Related]
12. Nicotine-induced tail-tremor and drug effects.
Gomita Y; Suemaru K; Furuno K; Araki Y
Pharmacol Biochem Behav; 1989 Dec; 34(4):817-21. PubMed ID: 2576144
[TBL] [Abstract][Full Text] [Related]
13. Antiparkinsonian-like effects of Plumbago scandens on tremorine-induced tremors methodology.
Morais LC; Quintans-Júnior LJ; Franco CI; Almeida JR; Almeida RN
Pharmacol Biochem Behav; 2004 Dec; 79(4):745-9. PubMed ID: 15582683
[TBL] [Abstract][Full Text] [Related]
14. Tremorine-oxotremorine-induced tremor, hypothermia and analgesia, and physostigmine toxicity, in mice after pretreatment with beta-adrenoceptor antagonists.
Barar FS; Madan BR
J Pharm Pharmacol; 1976 Apr; 28(4):286-9. PubMed ID: 6716
[TBL] [Abstract][Full Text] [Related]
15. Relationship of the behavioral effects of aprophen, atropine and scopolamine to antagonism of the behavioral effects of physostigmine.
Genovese RF; Elsmore TF; Witkin JM
Pharmacol Biochem Behav; 1990 Sep; 37(1):117-22. PubMed ID: 2263653
[TBL] [Abstract][Full Text] [Related]
16. Interaction of central serotonin and dopamine in the regulation of carbaryl-induced tremor.
Ray SK; Poddar MK
Eur J Pharmacol; 1990 Jun; 181(3):159-66. PubMed ID: 1696544
[TBL] [Abstract][Full Text] [Related]
17. [The antiataxic mechanism of TRH in rolling mouse Nagoya: the effects of pretreatment with dopaminergic and cholinergic drugs].
Matsui K; Ando K
Jikken Dobutsu; 1984 Oct; 33(4):465-9. PubMed ID: 6440800
[TBL] [Abstract][Full Text] [Related]
18. Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats.
Myhrer T; Enger S; Aas P
Pharmacol Biochem Behav; 2008 Jun; 89(4):633-8. PubMed ID: 18384867
[TBL] [Abstract][Full Text] [Related]
19. Centrally active antimuscarinic analogs of oxotremorine selectively block physostigmine-induced hypertension, but not peripheral muscarinic vasodepression.
Vargas HM; Ringdahl B
J Pharmacol Exp Ther; 1990 Apr; 253(1):165-70. PubMed ID: 2329503
[TBL] [Abstract][Full Text] [Related]
20. Influence of anticholinergic-antiparkinsonian agents on the effects of narcoanalgesic drugs in the rat.
Fischer E; Heller B; Lumbreras N
Experientia; 1973 Feb; 29(2):188-9. PubMed ID: 4144250
[No Abstract] [Full Text] [Related]
[Next] [New Search]
